Welcome

The Post-Finasteride Syndrome Foundation’s primary mission is to fund research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.

Read our FDA Citizen Petition to remove finasteride from the market.

Adverse drug reaction reports worldwide

Adverse drug reaction reports worldwide

PFS research studies published

PFS research studies published

Known suicides worldwide

Known suicides worldwide

Doctors & researchers speaking out

Doctors & researchers speaking out

Nations warning of PFS

Nations warning of PFS

National media reports worldwide

National media reports worldwide

Sources

Patient Services

Connect with other PFS patients

Consult knowledgeable doctors

Report your side effects

Read the latest research

Doctors & Researchers Speaking Out

Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020

Michael S. Irwig, MD, Attending Endocrinologist
Beth Israel Deaconess Medical Center

Even if the incidence of persistent sexual adverse events is 3% to 5%… approximately 900,000 to 1.5 million men would suffer persistent sexual and psychiatric adverse events.

[A]pproximately 30 million young men, worldwide, would be prescribed finasteride or dutasteride to treat male pattern hair loss. Even if the incidence of persistent sexual adverse events is 3% to 5%, which may be viewed as a small number, approximately 900,000 to 1.5 million men would suffer persistent sexual and psychiatric adverse events. By no means this would be considered a small number and should not be dismissed or ignored.

Post-finasteride syndrome: a surmountable challenge for clinicians: Fertility and Sterility, January 2020

Abdulmaged M. Traish, PhD, Professor of Biochemistry and Urology
Boston University School of Medicine

We wouldn’t recommend that any man take [finasteride], especially not young men.

We are certainly very cautious, because we see the side effects. We wouldn’t recommend that any man take [finasteride], especially not young men. The longer they take it, the greater the risk of experiencing persistent side effects, including after they’ve stopped.

Do Anti-Baldness Remedies Make You Impotent? Puls, SRF-TV, May 7, 2018

Doris Mannhard, MD, Urologist
University Hospital Zürich

FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.

Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.

FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000

Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research
US Food and Drug Administration

Reminder: Report PFS Symptoms to FDA MedWatch

SOMERSET, N.J., Oct. 29, 2013 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to the FDA MedWatch program. MedWatch is the U.S. Food and Drug Administration’s system for detecting safety-hazard signals for pharmaceutical products and medical devices. If a signal is detected, the FDA can issue safety alerts, […]

Clinical Study of Post-Finasteride Syndrome Launched at Baylor College of Medicine

SOMERSET, N.J., Aug. 21, 2013 – The Post-Finasteride Syndrome Foundation today announced the funding of a second major clinical study on post-finasteride syndrome (PFS), this one at Baylor College of Medicine (BCM) in Houston, Texas. Titled “Genetic and Epigenetic Studies on Post-Finasteride Syndrome Patients,” the research is being led by Mohit Khera (right), MD, MBA, […]

PFS Patient Query: Suicide Cases

  August 7, 2013   Dear Friends: The PFS Foundation is seeking information about patients who have taken finasteride or dutasteride, and who have attempted suicide or who have completed suicide. This is an area of active research interest and researchers are seeking to obtain medical records and other relevant material for such patients. To […]

2013 PFS Foundation Annual Address

Aug. 4, 2013 Dear Friends: When we incorporated the Post-Finasteride Syndrome Foundation in July 2012, our mission was clear: To fund research on the characterization, underlying biologic mechanisms and treatments of PFS while raising public awareness of this often life-altering condition afflicting thousands of men the world over. Now, on the occasion of our one-year […]

Clinical Study of Post-Finasteride Syndrome Launched at Brigham and Women’s Hospital

SOMERSET, N.J., July 1, 2013 – The Post-Finasteride Syndrome Foundation today announced the funding of a major clinical study on post-finasteride syndrome (PFS) at Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School. Titled “A Preliminary, Hypothesis-Generating Investigation of the Post-Finasteride Syndrome: Description of the Phenotype, and Elucidation of the Hormonal, Genetic […]